Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04263181 · ClinicalTrials.gov registry record
AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
A clinical trial of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.
- Active
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT04263181 is a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 80 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04263181, a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.
Conditions Studied
Interventions
- PROCEDURE Peripheral blood draw
- PROCEDURE Bone marrow aspirate
- PROCEDURE Buccal swab
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-01-29 |
| Est. Completion | 2027-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04263181
The ClinicalTrials.gov registry entry for NCT04263181 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (31% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Peripheral blood draw is the first listed.
NCT04263181 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04263181 about?
NCT04263181 is a clinical study titled "AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration". In this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.
What is the current status of trial NCT04263181?
This trial is currently active not recruiting. The enrollment target is 80 participants. The study started on 2020-01-29. Estimated completion is 2027-01-31.
What conditions does trial NCT04263181 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes.
What interventions are being tested in trial NCT04263181?
The interventions under investigation include: Peripheral blood draw (PROCEDURE), Bone marrow aspirate (PROCEDURE), Buccal swab (PROCEDURE).
Who is sponsoring clinical trial NCT04263181?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04263181 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
RECRUITING
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.